药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Intetumumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Intetumumab.
Difenoxin
Ibalizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ibalizumab.
Difenoxin
Lumretuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lumretuzumab.
Difenoxin
Tovetumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tovetumab.
Difenoxin
Dacetuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dacetuzumab.
Difenoxin
Bimagrumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bimagrumab.
Difenoxin
Blosozumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Blosozumab.
Difenoxin
Mavrilimumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mavrilimumab.
Difenoxin
Inebilizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Inebilizumab.
Difenoxin
Plozalizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Plozalizumab.
Difenoxin
Mogamulizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mogamulizumab.
Difenoxin
Bococizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bococizumab.
Difenoxin
Indusatumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Indusatumab vedotin.
Difenoxin
Fresolimumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fresolimumab.
Difenoxin
Dusigitumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dusigitumab.
Difenoxin
Fezakinumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fezakinumab.
Difenoxin
Ensituximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ensituximab.
Difenoxin
Tanezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tanezumab.
Difenoxin
Labetuzumab govitecan
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Labetuzumab govitecan.
Difenoxin
Vanucizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Vanucizumab.